P osttransplant survival in heart transplant recipients has progressively improved since heart transplants were first performed, an observation often referred to as the "era effect" in heart transplantation. [1] [2] [3] [4] [5] Although much of this improvement is due to improved survival in the early posttransplant period, recent multicenter registry reports also observed improvement in longer-term survival. 1, 2 Because posttransplant outcomes have been poorer historically in black (or nonwhite) recipients, 6 -11 it is important to know whether the era effect in posttransplant survival is due to improved survival in all or only some of the racial groups.
Clinical Perspective on p 160
Because the posttransplant care of heart transplant recipients is protocol driven at most centers and is expected to be the same irrespective of patient race, we hypothesized that the improvement in posttransplant survival in heart transplant recipients has benefited the major racial groups in the United States equally. The objective of this study was to compare the era effect for early (first 6 months posttransplant) and longer-term posttransplant survival in white, black, and Hispanic heart transplant recipients in the United States. We excluded patients who received a heart retransplant or multiorgan transplants. All subjects were followed from the time of heart transplant until death, retransplant, or the day of last observation on March 31, 2009.
Study Design
The primary study hypothesis was that black and Hispanic heart transplant recipients in the United States have experienced an improvement in early and longer-term posttransplant survival similar to that observed in white heart transplant recipients during the past 2 decades. We compared baseline characteristics and trends in posttransplant survival among white, black, and Hispanic heart transplant recipients in 5 successive eras (transplanted during the years 1987 to 1992, 1993 to 1996, 1997 to 2000, 2001 to 2004, and 2005 to 2008) in the OPTN database. We analyzed 2 time-to-event end points: early graft loss within 6 months posttransplant and longer-term graft loss. Graft loss was defined as a composite of death (all-cause mortality) and retransplantation. Longer-term, conditional survival was assessed in patients who survived the first 6 months posttransplant.
Demographic and clinical variables were defined at the time of transplant. Patient race/ethnicity, a mandatory variable, was reported by the transplant centers as one of the following: white, black, Hispanic/Latino, Asian, American Indian/Alaska Native, Native Hawaiian/Pacific Islander, multiracial, and other. Because of the small sample size for transplant recipients in minorities other than blacks and Hispanics (2.5% of all heart transplant recipients), these patients were not analyzed.
None of the subjects had any missing data for the variables age, sex, race/ethnicity, cardiac diagnosis, ventilator, extracorporeal membrane oxygenation, ventricular assist device, medical insurance (Medicaid), UNOS listing status, intra-aortic balloon pump, inotrope support, dialysis, and the date of transplant. For patients with missing data on other variables, we created an indicator variable, "variable not reported," for each such variable to allow these subjects to contribute their other risk factors in the multivariable models.
Statistical Analysis
Summary data are presented as median (25th, 75th percentile) or number (percent). Baseline characteristics among groups were compared using the 2 test for categorical and the Kruskal-Wallis test for continuous variables. Unadjusted survival rates were assessed using the Kaplan-Meier method. We developed a multivariable Cox proportional hazards model for early posttransplant survival using a forward selection procedure retaining variables significant at the 0.10 level based on a likelihood ratio test and then added the race and era variables to the model. A second multivariable Cox model was developed for longer-term, conditional survival with a similar approach, limiting analysis to recipients who survived the first 6 months posttransplant. The effect of era was modeled in 2 ways: as a continuous variable coded 1 to 5 from the earliest to the most recent time period and, using 1987 to 1992 as the reference group, with binary, indicator covariates for each subsequent period. For both early and longer-term survival, race-era interaction terms, with era as a continuous variable, were added to the main effect models to assess whether the improvement in posttransplant survival over time was modified by race. Stratified multivariable models were developed to confirm significant race-era interactions in the overall model. To assess whether racial differences in improvement in longer-term survival were related to transplant center experience, we performed multivariable analyses for recipients stratified by the total number of recipients in each center over 20 years (Ͻ250, 250 to 499, Ն500 recipients during the study duration to define low-, mid-, and high-volume centers). In all models, we fitted continuous variables with a restricted cubic spline to allow for the most flexible relationship between the variable and the outcome.
To assess whether racial differences in era effect could be attributed to differences in use of newer immune-suppression medications in these groups, we assessed racial trends in use of maintenance tacrolimus and mycophenolate mofetil at the time of hospital discharge following transplant and in first-year rejection episodes. Finally, we compared the groups for freedom from coronary artery disease diagnosis using OPTN annual follow-up data and Kaplan-Meier survival curves censoring patients at death. We evaluated racial differences in time to coronary artery diagnosis and era effect for coronary artery hazard in each group using a Cox proportional hazard model.
The data were analyzed using SAS version 9.1 (SAS Institute Inc; Cary, NC) and STATA version 10.0 (StataCorp; College Station, TX) statistical software. All statistical tests were 2-sided and PϽ0.05 was used to define statistical significance.
Results

Study Population
During the study period, 37 682 patients aged Ն18 years underwent their first heart transplant in the United States. Of these, 934 were from racial/ethnic groups other than those in the study and were excluded from further analysis. The remaining 36 748 patients formed the study cohort. Of these, 29 986 (81.6%) were white, 4745 (12.9%) were black, and 2017 (5.5%) were Hispanic. In the OPTN database, race and ethnicity are reported as 2 distinct variables; however, for all white, black, and Hispanic patients in the study cohort, race and ethnicity variables were reported to be concordant (identical). Table 1 summarizes baseline demographic and clinical characteristics of heart transplant recipients in the 3 racial groups. Compared to black and Hispanic patients, white patients were likely to be older and more likely to have ischemic cardiomyopathy given as their cardiac diagnosis (PϽ0.001). Black patients were more likely to be women, to have dilated cardiomyopathy, and to have a history of drug-treated hypertension than patients in the other groups. They also were more likely to be supported by a ventricular assist device, listed as status 1 or 1A at transplant, and have a serum creatinine Ͼ1.5 mg/dL at the time of their transplant. Hispanic patients had the highest prevalence of diabetes. White patients comprised a lower and black and Hispanic patients a higher proportion of transplant recipients in successive eras (Table 1) (PϽ0.001 for distribution by era). See online-only Data Supplement Figure and Table 1 for comparison of additional characteristics among groups.
Early (6-Month) Posttransplant Survival
Overall, death or retransplantation occurred in 17 000 transplant recipients during the study period (16 226 deaths and 774 retransplants). Early graft loss occurred in 4349 (11.8%) transplant recipients (4161 deaths, 188 retransplants). Unadjusted 6-month posttransplant survival improved from 86.3% in the earliest era (1987-1992) to 90.8% in the most recent era (2005) (2006) (2007) (2008) . Early posttransplant survival improved with time in all racial groups ( Figure 1A through 1C) .
In a multivariable model adjusted for patient factors and era of transplant, the risk of death or retransplant within 6 months posttransplant was significantly higher in black transplant recipients than in white recipients (hazard ratio [HR], 1.15; 95% CI, 1.05 to 1.26; Pϭ0.004) ( Table 2) . Early posttransplant survival improved significantly in successive eras (HR, 0.83; 95% CI, 0.80 to 0.87; PϽ0.001) ( Table 2) . Furthermore, when the transplant eras were modeled as binary, indicator variables with recipients during 1987 to 1992 as the reference group, the risk of death or retransplantation within the first 6 months posttransplant was 49% lower for transplant recipients in 2005 to 2008 than in the reference group (HR, 0.51; 95% CI, 0.43 to 0.60; PϽ0.001). When race-era interaction terms were added to the main effect model in Table 2 , they were not statistically significant (black-era interaction, Pϭ0.94; Hispanic-era interaction, Pϭ0.40).
Longer-Term, Conditional Survival
Overall, the annual rate of death or retransplantation in 6-month survivors was 4.3% in white, 5.5% in black, and 4.3% in Hispanic transplant recipients. In multivariable analysis, a significant race-era interaction was identified for longer-term survival (black-era interaction, PϽ0.001; Hispanic-era interaction, Pϭ0.06). In a model adjusted for baseline risk factors, longer-term survival improved in successive eras in white (HR, 0.95; 95% CI, 0.92 to 0.97; PϽ0.001) but not in black or Hispanic transplant recipients ( Table 3) . As a result, the risk of death or retransplantation in black and Hispanic recipients (versus white recipients) increased progressively during the 5 eras ( Figure 2 ). Other independent predictors of late death or retransplantation included ischemic etiology, diabetes, renal dysfunction, and Medicaid insurance.
In multivariable models stratified by race, race-era interaction findings demonstrated in Table 3 and Figure 2 were confirmed. Thus, longer-term survival improved in white (HR, 0.94; 95% CI, 0.91 to 0.97; PϽ0.001) but not in black or Hispanic transplant recipients (see online-only Data Supplement). In multivariable models stratified by era, black recipients were at a higher risk of longer-term graft loss (versus white recipients) in all eras, with an increase in relative risk from the earliest (HR, 1.59; 95% CI, 1.45 to 1.75; PϽ0.001) to the most recent (HR, 2.37; 95% CI, 1.86 to 3.02; PϽ0.001) era. The risk of longer-term graft loss in Hispanic recipients was similar to white recipients during the first 3 eras but was higher during 2001 to 2004 (HR, 1.25; 95% CI, 1.01 to 1.55; Pϭ0.04) and 2005 to 2008 (HR, 1.55; 95% CI, 1.08 to 2.22; Pϭ0.02) (see online-only Data Supplement).
There was no improvement in longer-term survival in any racial group in recipients from low-volume centers (Ͻ250 total recipients). The improvement in survival in white recipients from midvolume centers (250 to 499 total recipients) was of borderline statistical significance (HR, 0.95 for successive eras; Pϭ0.06) and was highly significant in white recipients from high-volume centers (HR, 0.88; PϽ0.001). Longer-term survival did not improve in black or Hispanic recipients in either mid-or high-volume centers.
Racial Trends in Immune Suppression, Rejection, and Coronary Artery Disease
The percentage of transplant recipients on tacrolimus immune suppression and those on mycophenolate immune suppression at hospital discharge increased in successive eras in all racial groups. The proportion of white, black, and Hispanic recipients on mycophenolate were similar in all eras, but a higher proportion of black recipients (versus white recipients) appeared to be on tacrolimus in successive eras ( Figure 3A and 3B).
First-year rejection data were not available for transplant recipients in the first and the majority of the second era. The percentage of recipients who were reported to have a rejection episode during the first posttransplant year declined from the third to the fifth era (1997 to 2000, 2001 to 2004, and 2005 to 2008) in white (56%, 40%, and 24%, respectively), black (62%, 43%, and 33%, respectively), and Hispanic (60%, 36%, and 26%, respectively) recipients.
The difference among racial groups for freedom from coronary artery disease was statistically significant (Pϭ0.02, log-rank test) (online-only Data Supplement Figure) , with a shorter time to diagnosis for black than for white recipients (HR, 1.13; 95% CI, 1.06 to 1.21). There was no difference between Hispanic and white recipients for time to coronary artery disease diagnosis (HR, 0.95; 95% CI, 0.86 to 1.04). There was no era effect for time to diagnosis of coronary artery disease in white (HR for successive eras, 1.02; 95% CI, 099 to 1.05), black (HR, 0.98; 95% CI, 0.92 to 1.05), or Hispanic (HR, 1.05; 95% CI, 0.94 to 1.17) recipients.
Discussion
In the present study, we analyzed trends in posttransplant survival in heart transplant recipients from 3 major US racial †Race-era interaction terms were interpreted in 2 ways: as era effect within racial groups (this table) and as racial differences in outcomes within all eras ( Figure 2 ).
Figure 2.
Widening racial disparities for longer-term survival, conditional on surviving the first 6 months after heart transplant. The reference group is white heart transplant recipients. The HRs and 95% CIs are adjusted for baseline risk factors (see Table 3 ). groups during the past 2 decades. There are 3 main findings of this study. First, the risk of death or retransplantation within 6 months posttransplant, adjusted for baseline risk factors at the time of transplant, has decreased equally in white, black, and Hispanic recipients during the past 2 decades. Second, among patients who survived the first 6 months posttransplant, longer-term survival has progressively improved in white but not in black or Hispanic recipients. As a result, disparities in longer-term posttransplant survival among racial groups have increased with time. Third, black heart transplant recipients have worse posttransplant outcomes than white recipients both during the early posttransplant period and on longer-term follow-up. For example, the risk of death or retransplantation in black recipients within the first 6 months posttransplant is 15% higher than in white recipients, and for longer-term follow-up, it is 111% higher than in white recipients in the current era. These disparities in posttransplant outcomes warrant further investigation and may be amenable to intervention.
Risk factors for early posttransplant mortality in our analysis included the listing diagnosis, the level of cardiac support (and thus the severity of heart failure), pretransplant anti-HLA antibodies Ͼ10%, male recipients who received a heart from a female donor, and comorbidity at the time of transplant ( Table  2 ). The finding that early outcomes have improved similarly among racial groups adjusted for these risk factors suggests that advances in recipient selection, the care of patients awaiting a heart transplant, perioperative care of transplant recipients, and immune suppression, which have contributed to improvement in early survival after heart transplantation, [3] [4] [5] have been implemented widely among centers and have benefited the racial groups equally. Several risk factors for early mortality, such as ventricular assist device support, pulmonary vascular resistance Ͼ3 Wood units, anti-HLA antibodies Ͼ10%, and administration of intravenous antibiotics Ͻ2 weeks before transplant were more prevalent in black recipients, and residual confounding with respect to these risk factors could have contributed to their worse early outcomes. Risk factors not captured in the OPTN database, such as differences in access to care, illness severity at presentation, and rate of disease progression, also could have contributed to these outcome differences.
We were surprised to find that the improvement in longerterm survival has been limited to white heart transplant recipients. Although we did anticipate better conditional survival in recipients from more recent years, 1,2 we expected this finding in either all racial groups or primarily in higherrisk black recipients (because recognition of a risk factor often leads to efforts to improve outcomes associated with that risk factor). Several potential mechanisms have been invoked to explain worse longer-term outcomes in black heart transplant recipients. These mechanisms include biological factors such as a higher prevalence of pretransplant and posttransplant hypertension, 12 a higher likelihood of donorrecipient HLA mismatch, 13 and immunologic and metabolic differences from whites. Black recipients have a higher prevalence of genotypes associated with reduced immune suppression exposure and efficacy as well as genotypes associated with a proinflammatory state. 14 Lower socioeconomic position and fewer years of formal education, known to be more prevalent in the black population, have been previously associated with worse posttransplant outcomes. 12, 15, 16 A similar association of black race with worse graft survival also has been described in renal transplantation and has been attributed to a combination of genetic, immunologic, and socioeconomic factors. [17] [18] [19] These biological and socioeconomic factors also may explain the lack of improvement in longer-term survival in black recipients observed in the present study. Our analysis shows that although rejection rates have decreased progressively in all groups, a modestly higher proportion of black recipients had a rejection episode during the first posttransplant year in all eras. The risk of developing graft coronary artery disease was also higher in black recipients, suggesting that racial differences in longerterm survival are partly due to rejection-related mechanisms. Although black and Hispanic transplant recipients in the current study were 3 times as likely to have Medicaid insurance as white recipients, the reported race effects were seen after adjusting for insurance. Given that newer immune suppression agents (eg, mycophenolate mofetil, tacrolimus, and sirolimus) reduce rejection rates, prevent progression of cardiac allograft vasculopathy, and improve graft and patient survival in heart transplant recipients, 5,20 -23 our finding that a similar or higher percentage of black and Hispanic transplant recipients (versus white recipients) received maintenance mycophenolate and tacrolimus in all eras makes it unlikely that the lack of improvement in longerterm survival in these recipients was due to a disparity in choice of immune suppression.
A few single-center studies have reported equivalent posttransplant survival in white and black heart transplant recipients and have attributed their success in black recipients to either newer, more efficacious immune suppression protocols or to specialized care (ie, a quality improvement initiative at the center). 20, 21 Equivalence of outcomes in white and black transplant recipients using newer immune suppression also has been reported recently in renal transplantation. 24 These preliminary reports suggest that approaches that combine current immune suppression agents with quality control initiatives and with interventions to reduce disparities may help to bridge survival differences among racial groups despite their underlying immunologic and metabolic differences and may improve overall posttransplant survival. 25 For example, enhanced patient education with respect to medical management and symptoms of rejection in those with limited formal schooling and improved support system for patients with socioeconomic challenges that allows easy access to transplant team members may help to improve longer-term outcomes in minorities.
Our results also demonstrate that minorities represent an increasing proportion of heart transplant recipients in the United States. This demographic shift not only is expected as the racial distribution of the US population changes over time, but also may be due to other factors, such as an increase in referral of minority patients to transplant centers and a higher incidence of heart failure in minorities, particularly blacks. 26, 27 Further improvement in survival after heart transplant will require a concurrent use of 2 strategies similar to those described for preventing cardiovascular disease 28 : (1) developing interventions that improve outcomes in all heart transplant recipients and (2) identifying transplant recipients at high risk of graft loss and targeting interventions to improve their outcomes. The present analysis provides a framework for such interventions by describing the magnitude of racial disparity associated with early and longer-term posttransplant survival. Reduction and elimination of racial disparities in health care and in health outcomes are national priorities in the United States. 29 Because racial disparities have complex, multifactorial origins, interventions likely to succeed in reducing disparities in posttransplant outcomes are also likely to be multilevel. 30 This study has a few limitations. First, being a retrospective analysis of a national database, the quality control of these data may be variable among transplant centers. However, because UNOS uses the OPTN data to mediate organ allocation in the United States and to evaluate and report transplant center performance, certain safeguards to data quality are to be expected. Second, race was analyzed as reported by the transplant centers, and there is a possibility that some recipients were misclassified. However, a nondifferential misclassification of race would likely result in a loss of statistical power, which was not a major problem in this study because of the relatively large sample size. Finally, the duration of follow-up was different in transplant recipients from different eras. Although Cox models allowed us to evaluate recipients with different duration of follow-up, these models may not predict future survival accurately in transplant recipients from the more recent eras.
In conclusion, the progressive improvement in early posttransplant survival during the past 2 decades has benefited white, black, and Hispanic heart transplant recipients equally. Longer-term survival has improved in white but not in black or Hispanic transplant recipients, resulting in a more marked disparity in outcomes in the current era. Black heart transplant recipients are at higher risk of early and longer-term graft loss compared to other groups. Targeted interventions in high-risk transplant recipients may improve long-term and overall survival in heart transplantation.
